Suppr超能文献

T4期肺癌的扩大手术

Extended operation for T4 lung carcinoma.

作者信息

Shirakusa T, Kawahara K, Iwasaki A, Okabayashi K, Shiraishi T, Yoneda S, Yoshinaga Y, Matsuzoe D, Watanabe K

机构信息

Second Department of Surgery, School of Medicine, Fukuoka University, Nanakuma 7-45-1 Jonanku, Fukuoka 814-0180, Japan.

出版信息

Ann Thorac Cardiovasc Surg. 1998 Jun;4(3):110-8.

PMID:9660907
Abstract

The extended surgery for T4 lung carcinoma was reviewed. From literature in the last decade, the 5-year survival rate has been under 10% worldwide. However a more favorable prognosis will be expected nowadays because of the progress of perioperative intensive care and appearance of effective anticancerous agents for induction chemotherapy. We compared the results of surgery for T4 lung carcinoma from 1978 to 1989, to those from 1992 to 1997. The 3 and 5-year survivals in the former period were 6.8% respectively, however in the latter period the 3-year survival rate rose to 24.6%. In patients with T4, the prognoses are different according to the involved organs by lung carcinoma. Generally, combined resection of the trachea, carina, descending aorta and left atrium show better prognoses compared to that of the esophagus and liver. We consider that malignant pleural effusion with N2 should not be the object for panpleuropneumonectomy. In our series from 1992 to 1997 median survival time (MST) of T4 with N0 or N1 was 25.5 months, on the other hand MST with N2 or N3 was 14.2 months. Histologically patients with squamous cell carcinoma showed a better prognosis than those with adenocarcinoma. From these results, in the extended operation for T4 we may expect more favorable prognoses in cases with involvements of the trachea, carina, aorta and left atrium, and with N0 or N1, histologically squamous cell carcinoma.

摘要

对T4期肺癌的扩大手术进行了回顾。从过去十年的文献来看,全球范围内5年生存率一直低于10%。然而,由于围手术期重症监护的进展以及诱导化疗有效抗癌药物的出现,如今有望获得更有利的预后。我们比较了1978年至1989年与1992年至1997年T4期肺癌的手术结果。前一时期的3年和5年生存率分别为6.8%,而在后一时期,3年生存率升至24.6%。在T4期患者中,根据肺癌所累及的器官不同,预后也有所不同。一般来说,与气管、隆突、降主动脉和左心房联合切除相比,与食管和肝脏联合切除的预后更好。我们认为伴有N2的恶性胸腔积液不应作为全胸膜肺切除术的对象。在我们1992年至1997年的系列研究中,N0或N1的T4期患者的中位生存时间(MST)为25.5个月,另一方面,N2或N3的患者的MST为14.2个月。组织学上,鳞状细胞癌患者的预后比腺癌患者更好。从这些结果来看,在T4期的扩大手术中,对于累及气管、隆突、主动脉和左心房且为N0或N1、组织学为鳞状细胞癌的病例,我们可能预期会有更有利的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验